REFERENCES
1. Keilholz, U.; Ascierto, P.; Dummer, R.; et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann. Oncol. 2020, 31, 1435-48.
2. Atkins, M. B.; Curiel-Lewandrowski, C.; Fisher, D. E.; et al. The state of melanoma: emergent challenges and opportunities. Clin. Cancer. Res. 2021, 27, 2678-97.
3. Li, H.; Bian, Y.; Xiahou, Z.; Zhao, Z.; Zhao, F.; Zhang, Q. The cellular signaling crosstalk between memory B cells and tumor cells in nasopharyngeal carcinoma cannot be overlooked: Their involvement in tumor progression and treatment strategy is significant. J. Cancer. 2025, 16, 288-314.
4. Huang, S. K.; Hoon, D. S. Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Mol. Oncol. 2015, 10, 450-63.
5. Sivapalan, L.; Murray, J. C.; Canzoniero, J. V.; et al. Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. J. Immunother. Cancer. 2023, 11, e005924.
6. Patel, R. P.; Somasundram, P. M.; Smith, L. K.; Sheppard, K. E.; Mcarthur, G. A. The therapeutic potential of targeting minimal residual disease in melanoma. Clin. Transl. Med. 2023, 13, e1197.
7. Tirosh, I.; Izar, B.; Prakadan, S. M.; et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 2016, 352, 189-96.
8. Whiteside, T. L. Biology of extracellular vesicles and the potential of tumor-derived vesicles for subverting immunotherapy of cancer. J. Immunother. Cancer. 2025, 13, e010376.
9. Zou, Y.; Zhou, Y.; Li, G.; Dong, Y.; Hu, S. Clinical applications of extracellular vesicles: recent advances and emerging trends. Front. Bioeng. Biotechnol. 2025, 13, 1671963.
10. Welsh, J. A.; Goberdhan, D. C. I.; O'driscoll, L.; et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J. Extracell. Vesicle. 2024, 13, e12404.
11. Ragni, E. Extracellular vesicles: recent advances and perspectives. Front. Biosci. 2025, 30, 36405.
12. Tang, H.; Yu, D.; Zhang, J.; et al. The new advance of exosome-based liquid biopsy for cancer diagnosis. J. Nanobiotechnol. 2024, 22, 610.
13. Ghanam, J.; Lichá, K.; Chetty, V. K.; et al. Unravelling the significance of extracellular vesicle-associated DNA in cancer biology and its potential clinical applications. J. Extracell. Vesicle. 2025, 14, e70047.
14. Andre, M.; Caobi, A.; Miles, J. S.; Vashist, A.; Ruiz, M. A.; Raymond, A. D. Diagnostic potential of exosomal extracellular vesicles in oncology. BMC. Cancer. 2024, 24, 322.
15. Li, Z.; Gao, Y.; Cao, Y.; et al. Extracellular RNA in melanoma: advances, challenges, and opportunities. Front. Cell. Dev. Biol. 2023, 11, 1141543.
16. Zhan, Y.; Yang, Z.; Zeng, H.; Yu, J.; Chen, X.; Wu, Y. Extracellular vesicle-derived non-coding RNAs in remodeling melanoma. Biomed. Pharmacother. 2024, 172, 116213.
17. Slusher, N.; Jones, N.; Nonaka, T. Liquid biopsy for diagnostic and prognostic evaluation of melanoma. Front. Cell. Dev. Biol. 2024, 12, 1420360.
18. Liu, J. J. J.; Liu, D.; To, S. K. Y.; Wong, A. S. T. Exosomes in cancer nanomedicine: biotechnological advancements and innovations. Mol. Cancer. 2025, 24, 166.
19. Ovchinnikova, L. A.; Lomakin, Y. A. Extracellular vesicles as a source of biomarkers for cancer diagnosis. Acta. Nat. 2025, 17, 28-40.
20. Babaei, S.; Fadaee, M.; Abbasi-Kenarsari, H.; Shanehbandi, D.; Kazemi, T. Exosome-based immunotherapy as an innovative therapeutic approach in melanoma. Cell. Commun. Signal. 2024, 22, 527.
21. Di Bella, M. A. Overview and update on extracellular vesicles: considerations on exosomes and their application in modern medicine. Biology 2022, 11, 804.
22. Zhang, Y.; Lan, M.; Chen, Y. Minimal information for studies of extracellular vesicles (MISEV): ten-year evolution (2014-2023). Pharmaceutics 2024, 16, 1394.
23. Di Bella, M. A.; Taverna, S. Extracellular vesicles: diagnostic and therapeutic applications in cancer. Biology 2024, 13, 716.
24. Yang, C.; Xue, Y.; Duan, Y.; Mao, C.; Wan, M. Extracellular vesicles and their engineering strategies, delivery systems, and biomedical applications. J. Controlled. Release. 2024, 365, 1089-123.
25. Zhang, Q.; Jeppesen, D. K.; Higginbotham, J. N.; Franklin, J. L.; Coffey, R. J. Comprehensive isolation of extracellular vesicles and nanoparticles. Nat. Protoc. 2023, 18, 1462-87.
26. Carney, R. P.; Mizenko, R. R.; Bozkurt, B. T.; et al. Harnessing extracellular vesicle heterogeneity for diagnostic and therapeutic applications. Nat. Nanotechnol. 2024, 20, 14-25.
27. Li, B.; Wu, W.; Xu, W.; Qian, H.; Ji, C. Advances of extracellular vesicles isolation and detection frontier technology: from heterogeneity analysis to clinical application. J. Nanobiotechnol. 2025, 23, 678.
28. Woo, H.; Nam, Y.; Park, H. G.; Lee, H. Bridging laboratory innovation to translational research and commercialization of extracellular vesicle isolation and detection. Biosens. Bioelectron. 2025, 282, 117475.
29. Poggio, M.; Hu, T.; Pai, C.; et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell 2019, 177, 414-27.e13.
30. Urzì, O.; Olofsson Bagge, R.; Crescitelli, R. Extracellular vesicles in uveal melanoma - Biological roles and diagnostic value. Cancer. Lett. 2025, 615, 217531.
31. Dong, X.; Lin, Y.; Li, K.; et al. Consensus statement on extracellular vesicles in liquid biopsy for advancing laboratory medicine. Clin. Chem. Lab. Med. 2025, 63, 465-82.
32. Asleh, K.; Dery, V.; Taylor, C.; Davey, M.; Djeungoue-Petga, M.; Ouellette, R. J. Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology. Biomark. Res. 2023, 11, 99.
33. Liu, J.; Hu, X.; Xin, W.; Wang, X. Exosomal non-coding RNAs: a new approach to melanoma diagnosis and therapeutic strategy. Curr. Med. Chem. 2024, 31, 6084-109.
34. Ricciardi, E.; Giordani, E.; Ziccheddu, G.; et al. Metastatic melanoma: liquid biopsy as a new precision medicine approach. Int. J. Mol. Sci. 2023, 24, 4014.
35. Minami, S.; Chikazu, D.; Ochiya, T.; Yoshioka, Y. Extracellular vesicle-based liquid biopsies in cancer: Future biomarkers for oral cancer. Transl. Oncol. 2023, 38, 101786.
36. Mondal, S. K.; Whiteside, T. L. Proteomic profiles of melanoma cell-derived exosomes in plasma: discovery of potential biomarkers of melanoma progression. Melanoma. Res. 2021, 31, 472-5.
37. Lattmann, E.; Räss, L.; Tognetti, M.; et al. Size-exclusion chromatography combined with DIA-MS enables deep proteome profiling of extracellular vesicles from melanoma plasma and serum. Cell. Mol. Life. Sci. 2024, 81, 90.
38. Clancy, J. W.; D'souza-Schorey, C. Tumor-derived extracellular vesicles: multifunctional entities in the tumor microenvironment. Annu. Rev. Pathol. Mech. Dis. 2023, 18, 205-29.
39. Helvind, N. M.; Brinch-Møller Weitemeyer, M.; Chakera, A. H.; et al. Stage-specific risk of recurrence and death from melanoma in Denmark, 2008-2021: a national observational cohort study of 25 720 patients with stage IA to IV melanoma. JAMA. Dermatol. 2023, 159, 1213.
40. Spiliopoulou, P.; Holanda Lopes, C. D.; Spreafico, A. Promising and minimally invasive biomarkers: targeting melanoma. Cells 2023, 13, 19.
41. Serratì, S.; Guida, M.; Di Fonte, R.; et al. Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. Mol. Cancer. 2022, 21, 20.
42. Sun, L.; Wei, X.; Zhao, Q.; et al. Dynamic change of PD-L2 on circulating plasma extracellular vesicles as a predictor of treatment response in melanoma patients receiving anti-PD-1 therapy. J. Extracell. Vesicle. 2025, 14, e70054.
43. Hsu, C.; Chandramoorthy, H. C.; Mohammed, J. S.; et al. Exosomes as key mediators in immune and cancer cell interactions: insights in melanoma progression and therapy. Arch. Dermatol. Res. 2025, 317, 729.
44. Serrano, D. R.; Juste, F.; Anaya, B. J.; et al. Exosome-based drug delivery: a next-generation platform for cancer, infection, neurological and immunological diseases, gene therapy and regenerative medicine. Pharmaceutics 2025, 17, 1336.
45. Johnson, V.; Vasu, S.; Kumar, U. S.; Kumar, M. Surface-engineered extracellular vesicles in cancer immunotherapy. Cancers 2023, 15, 2838.
46. Kim, H. I.; Park, J.; Zhu, Y.; Wang, X.; Han, Y.; Zhang, D. Recent advances in extracellular vesicles for therapeutic cargo delivery. Exp. Mol. Med. 2024, 56, 836-49.
47. Chen, Y.; Luh, F.; Ho, Y.; Yen, Y. Exosomes: a review of biologic function, diagnostic and targeted therapy applications, and clinical trials. J. Biomed. Sci. 2024, 31, 67.
48. Brezgin, S.; Danilik, O.; Yudaeva, A.; et al. Basic guide for approaching drug delivery with extracellular vesicles. Int. J. Mol. Sci. 2024, 25, 10401.
49. Abbasi-malati, Z.; Azizi, S. G.; Milani, S. Z.; et al. Tumorigenic and tumoricidal properties of exosomes in cancers; a forward look. Cell. Commun. Signal. 2024, 22, 130.
50. Xia, Y.; Zhang, J.; Liu, G.; Wolfram, J. Immunogenicity of extracellular vesicles. Adv. Mater. 2024, 36, 2403199.
51. Ziogas, D. C.; Theocharopoulos, C.; Koutouratsas, T.; Haanen, J.; Gogas, H. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: what we have to overcome? Cancer. Treat. Rev. 2023, 113, 102499.
52. Fernandez, M. F.; Choi, J.; Sosman, J. New approaches to targeted therapy in Melanoma. Cancers 2023, 15, 3224.
53. Yin, G.; Guo, W.; Huang, Z.; Chen, X. Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis. Melanoma. Res. 2022, 32, 71-8.
54. Van Delen, M.; Derdelinckx, J.; Wouters, K.; Nelissen, I.; Cools, N. A systematic review and meta-analysis of clinical trials assessing safety and efficacy of human extracellular vesicle-based therapy. J. Extracell. Vesicle. 2024, 13, e12458.
55. Xu, G.; Jin, J.; Fu, Z.; et al. Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies. Sig. Transduct. Target. Ther. 2025, 10, 255.
56. Su, X.; Wang, H.; Li, Q.; Chen, Z. Extracellular vesicles: a review of their therapeutic potentials, sources, biodistribution, and administration routes. Int. J. Nanomed. 2025, 20, 3175-99.
57. Kang, M.; Jordan, V.; Blenkiron, C.; Chamley, L. W. Biodistribution of extracellular vesicles following administration into animals: a systematic review. J. Extracell. Vesicle. 2021, 10, e12085.
58. Chen, T.; Chen, D.; Su, W.; Liang, J.; Liu, X.; Cai, M. Extracellular vesicles as vital players in drug delivery: a focus on clinical disease treatment. Front. Bioeng. Biotechnol. 2025, 13, 1600227.
59. Humbert, C.; Cordier, C.; Drut, I.; et al. GMP-compliant process for the manufacturing of an extracellular vesicles-enriched secretome product derived from cardiovascular progenitor cells suitable for a phase I clinical trial. J. Extracell. Vesicle. 2025, 14, e70145.
60. Akbani, R.; Akdemir, K. C.; Aksoy, B. A.; et al. Genomic classification of cutaneous melanoma. Cell 2015, 161, 1681-96.
61. Moran, B.; Silva, R.; Perry, A. S.; Gallagher, W. M. Epigenetics of malignant melanoma. Semin. Cancer. Biol. 2018, 51, 80-8.
62. Sarkar, D.; Leung, E. Y.; Baguley, B. C.; Finlay, G. J.; Askarian-Amiri, M. E. Epigenetic regulation in human melanoma: past and future. Epigenetics 2015, 10, 103-21.
63. Mannavola, F.; D’oronzo, S.; Cives, M.; et al. Extracellular vesicles and epigenetic modifications are hallmarks of melanoma progression. Int. J. Mol. Sci. 2019, 21, 52.
64. Kalluri, R.; Lebleu, V. S. The biology,function, and biomedical applications of exosomes. Science 2020, 367, eaau6977.
65. Willms, E.; Cabañas, C.; Mäger, I.; Wood, M. J. A.; Vader, P. Extracellular vesicle heterogeneity: subpopulations, isolation techniques, and diverse functions in cancer progression. Front. Immunol. 2018, 9, 738.
66. Zaborowski, M. P.; Balaj, L.; Breakefield, X. O.; Lai, C. P. Extracellular vesicles: composition, biological relevance, and methods of study. Bioscience 2015, 65, 783-97.
67. Yáñez-mó, M.; Siljander, P. R. M.; Andreu, Z.; et al. Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicle. 2015, 4, 27066.
68. Lespagnol, A.; Duflaut, D.; Beekman, C.; et al. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell. Death. Differ. 2008, 15, 1723-33.
69. Payandeh, Z.; Khalili, S.; Somi, M. H.; et al. PD-1/PD-L1-dependent immune response in colorectal cancer. J. Cell. Physiol. 2020, 235, 5461-75.
70. Jiang, Y.; Zhao, X.; Fu, J.; Wang, H. Progress and challenges in precise treatment of tumors with PD-1/PD-L1 blockade. Front. Immunol. 2020, 11, 339.
71. Wang, B.; Bai, W.; Ma, H.; Li, F. Regulatory effect of PD1/PD-Ligand 1 (PD-L1) on treg cells in patients with idiopathic pulmonary fibrosis. Med. Sci. Monit. 2020, 26, 927577.
72. Shergold, A. L.; Millar, R.; Nibbs, R. J. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. Pharmacol. Res. 2019, 145, 104258.
73. Cloughesy, T. F.; Mochizuki, A. Y.; Orpilla, J. R.; et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat. Med. 2019, 25, 477-86.
74. Chen, G.; Huang, A. C.; Zhang, W.; et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 2018, 560, 382-6.
75. Ricklefs, F. L.; Alayo, Q.; Krenzlin, H.; et al. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci. Adv. 2018, 4, eaar2766.
76. Theodoraki, M.; Yerneni, S. S.; Hoffmann, T. K.; Gooding, W. E.; Whiteside, T. L. Clinical significance of PD-L1+ exosomes in plasma of head and neck cancer patients. Clin. Cancer. Res. 2018, 24, 896-905.
77. Yang, Y.; Li, C.; Chan, L.; et al. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell. Res. 2018, 28, 862-4.
78. Fleming, V.; Hu, X.; Weller, C.; et al. Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling. Cancer. Res. 2019, 79, 4715-28.
79. Du, Z.; Feng, Y.; Zhang, H.; Liu, J.; Wang, J. Melanoma-derived small extracellular vesicles remodel the systemic onco-immunity via disrupting hematopoietic stem cell proliferation and differentiation. Cancer. Lett. 2022, 545, 215841.
80. Maus, R. L. G.; Jakub, J. W.; Nevala, W. K.; et al. Human melanoma-derived extracellular vesicles regulate dendritic cell maturation. Front. Immunol. 2017, 8, 358.
81. Valenti, R.; Huber, V.; Filipazzi, P.; et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-β-mediated suppressive activity on t lymphocytes. Cancer. Res. 2006, 66, 9290-8.
82. Hosseini, R.; Asef-kabiri, L.; Yousefi, H.; et al. The roles of tumor-derived exosomes in altered differentiation, maturation and function of dendritic cells. Mol. Cancer. 2021, 20, 83.
83. Marton, A.; Vizler, C.; Kusz, E.; et al. Melanoma cell-derived exosomes alter macrophage and dendritic cell functions in vitro. Immunol. Lett. 2012, 148, 34-8.
84. Düchler, M.; Czernek, L.; Peczek, L.; Cypryk, W.; Sztiller-Sikorska, M.; Czyz, M. Melanoma-derived extracellular vesicles bear the potential for the induction of antigen-specific tolerance. Cells 2019, 8, 665.
85. Sharma, P.; Diergaarde, B.; Ferrone, S.; Kirkwood, J. M.; Whiteside, T. L. Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. Sci. Rep. 2020, 10, 92.
86. Whiteside, T. L. Immunosuppressive functions of melanoma cell-derived exosomes in plasma of melanoma patients. Front. Cell. Dev. Biol. 2023, 10, 1080925.
87. Crucitta, S.; Cucchiara, F.; Marconcini, R.; et al. TGF-β mRNA levels in circulating extracellular vesicles are associated with response to anti-PD1 treatment in metastatic melanoma. Front. Mol. Biosci. 2024, 11, 1288677.
88. Tatischeff, I. Extracellular vesicle-DNA: the next liquid biopsy biomarker for early cancer diagnosis? Cancers 2023, 15, 1456.
89. Belviso, I.; Pastore, R.; Mileo, A.; et al. The role of fibroblasts in melanoma development: from tumor microenvironment remodeling to pre-metastatic niche formation. Int. J. Mol. Sci. 2025, 26, 6132.
90. Lu, M.; Yang, Y. Exosomal PD-L1 in cancer and other fields: recent advances and perspectives. Front. Immunol. 2024, 15, 1395332.
91. Chen, J.; Song, Y.; Miao, F.; et al. PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8+ T cell exhaustion during metastasis. Cancer. Sci. 2021, 112, 3437-54.
92. Liu, N.; Zhang, J.; Yin, M.; et al. Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization. Mol. Ther. 2021, 29, 2321-34.
93. Christofides, A.; Strauss, L.; Yeo, A.; Cao, C.; Charest, A.; Boussiotis, V. A. The complex role of tumor-infiltrating macrophages. Nat. Immunol. 2022, 23, 1148-56.
94. Gerloff, D.; Lützkendorf, J.; Moritz, R. K.; et al. Melanoma-derived exosomal miR-125b-5p educates tumor associated macrophages (TAMs) by targeting lysosomal acid lipase A (LIPA). Cancers 2020, 12, 464.
95. Wang, R.; Zhu, T.; Hou, B.; Huang, X. An iPSC-derived exosome-pulsed dendritic cell vaccine boosts antitumor immunity in melanoma. Mol. Ther. 2023, 31, 2376-90.
96. Tucci, M.; Mannavola, F.; Passarelli, A.; Stucci, L. S.; Cives, M.; Silvestris, F. Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity. Oncotarget 2018, 9, 20826-37.
97. Zhou, J.; Yang, Y.; Wang, W.; et al. Melanoma-released exosomes directly activate the mitochondrial apoptotic pathway of CD4+ T cells through their microRNA cargo. Exp. Cell. Res. 2018, 371, 364-71.
98. Li, X.; Liu, Y.; Yang, L.; Jiang, Y.; Qian, Q. TIM-3 shuttled by MV3 cells-secreted exosomes inhibits CD4+ T cell immune function and induces macrophage M2 polarization to promote the growth and metastasis of melanoma cells. Transl. Oncol. 2022, 18, 101334.
99. De Cicco, P.; Ercolano, G.; Ianaro, A. The new era of cancer immunotherapy: targeting myeloid-derived suppressor cells to overcome immune evasion. Front. Immunol. 2020, 11, 1680.
100. Peinado, H.; Alečković, M.; Lavotshkin, S.; et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18, 883-91.
101. Peinado, H.; Zhang, H.; Matei, I. R.; et al. Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer. 2017, 17, 302-17.
102. Kim, J.; Afshari, A.; Sengupta, R.; et al. Replication study: melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. eLife 2018, 7, e39944.
103. Rinderknecht, M.; Detmar, M. Tumor lymphangiogenesis and melanoma metastasis. J. Cell. Physiol. 2008, 216, 347-54.
104. Hood, J. L.; San, R. S.; Wickline, S. A. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer. Res. 2011, 71, 3792-801.
105. García-Silva, S.; Benito-Martín, A.; Nogués, L.; et al. Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism. Nat. Cancer. 2021, 2, 1387-405.
106. Hu, T.; Hu, J. Melanoma-derived exosomes induce reprogramming fibroblasts into cancer-associated fibroblasts via Gm26809 delivery. Cell. Cycle. 2019, 18, 3085-94.
107. Shelton, M.; Anene, C.; Nsengimana, J.; Roberts, W.; Newton-Bishop, J.; Boyne, J. The role of CAF derived exosomal microRNAs in the tumour microenvironment of melanoma. Biochim. Biophys. Acta. 2021, 1875, 188456.
108. Benito-Martín, A.; Jasiulionis, M. G.; García-Silva, S. Extracellular vesicles and melanoma: new perspectives on tumor microenvironment and metastasis. Front. Cell. Dev. Biol. 2023, 10, 1061982.
109. Wang, C.; Wang, Y.; Chang, X.; et al. Melanoma-derived exosomes endow fibroblasts with an invasive potential via miR-21 target signaling pathway. Cancer. Manag. Res. 2020, 12, 12965-74.
110. Tagliatela, A. C.; Hempstead, S. C.; Hibshman, P. S.; et al. Coronin 1C inhibits melanoma metastasis through regulation of MT1-MMP-containing extracellular vesicle secretion. Sci. Rep. 2020, 10, 11958.
111. Pavlides, S.; Whitaker-Menezes, D.; Castello-Cros, R.; et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell. Cycle. 2014, 8, 3984-4001.
112. Lazar, I.; Clement, E.; Dauvillier, S.; et al. Adipocyte exosomes promote melanoma aggressiveness through fatty acid oxidation: a novel mechanism linking obesity and cancer. Cancer. Res. 2016, 76, 4051-7.
113. Clement, E.; Lazar, I.; Attané, C.; et al. Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells. EMBO. J. 2020, 39, EMBJ2019102525.
114. Medhin, L. B.; Beasley, A. B.; Warburton, L.; Amanuel, B.; Gray, E. S. Extracellular vesicles as a liquid biopsy for melanoma: are we there yet? Semin. Cancer. Biol. 2023, 89, 92-8.
115. Wu, N.; Sun, H.; Sun, Q.; et al. Circulating microRNAs as diagnostic biomarkers for melanoma: a systematic review and meta-analysis. BMC. Cancer. 2023, 23, 414.
116. Hu, C.; Jiang, W.; Lv, M.; et al. Potentiality of exosomal proteins as novel cancer biomarkers for liquid biopsy. Front. Immunol. 2022, 13, 792046.
117. Wang, M.; Cai, Y.; Peng, Y.; Xu, B.; Hui, W.; Jiang, Y. Exosomal LGALS9 in the cerebrospinal fluid of glioblastoma patients suppressed dendritic cell antigen presentation and cytotoxic T-cell immunity. Cell. Death. Dis. 2020, 11, 896.
118. Shimada, Y.; Matsubayashi, J.; Kudo, Y.; et al. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer. Sci. Rep. 2021, 11, 7830.
119. Kluszczynska, K.; Czyz, M. Extracellular vesicles-based cell-cell communication in melanoma: new perspectives in diagnostics and therapy. Int. J. Mol. Sci. 2023, 24, 965.
120. Van Niel, G.; D'angelo, G.; Raposo, G. Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell. Biol. 2018, 19, 213-28.
121. Théry, C.; Witwer, K. W.; Aikawa, E.; et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicle. 2018, 7, 1535750.
122. Ullah, M. The future of bioorthogonal-chemistry for targeting of exosomes in precision medicine. Oncotarget 2022, 13, 1303-4.
123. Rayamajhi, S.; Sipes, J.; Tetlow, A. L.; Saha, S.; Bansal, A.; Godwin, A. K. Extracellular vesicles as liquid biopsy biomarkers across the cancer journey: from early detection to recurrence. Clin. Chem. 2024, 70, 206-19.
124. Xia, C.; Yin, S.; To, K. K. W.; Fu, L. CD39/CD73/A2AR pathway and cancer immunotherapy. Mol. Cancer. 2023, 22, 44.
125. Kurago, Z.; Guo, G.; Shi, H.; et al. Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy. Front. Immunol. 2023, 14, 1212209.
126. Saigí, M.; Mesía-Carbonell, O.; Barbie, D. A.; Guillamat-Prats, R. Unraveling the intricacies of CD73/adenosine signaling: the pulmonary immune and stromal microenvironment in lung cancer. Cancers 2023, 15, 5706.
127. Turiello, R.; Capone, M.; Morretta, E.; et al. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents. J. Immunother. Cancer. 2022, 10, e004043.
128. Yang, Y.; Zhu, L.; Xu, Y.; et al. The progress and prospects of targeting the adenosine pathway in cancer immunotherapy. Biomark. Res. 2025, 13, 75.
129. Rodrigues-junior, D. M.; Tsirigoti, C.; Lim, S. K.; Heldin, C.; Moustakas, A. Extracellular vesicles and transforming growth factor β signaling in cancer. Front. Cell. Dev. Biol. 2022, 10, 849938.
130. De Miguel-Perez, D.; Russo, A.; Gunasekaran, M.; et al. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer. Cancer 2022, 129, 521-30.
131. Biagioni, A.; Laurenzana, A.; Menicacci, B.; et al. uPAR-expressing melanoma exosomes promote angiogenesis by VE-Cadherin, EGFR and uPAR overexpression and rise of ERK1,2 signaling in endothelial cells. Cell. Mol. Life. Sci. 2020, 78, 3057-72.
132. Porcelli, L.; Guida, M.; De, Summa. S.; et al. uPAR+ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients. J. Immunother. Cancer. 2021, 9, e002372.
133. Serratì, S.; Di Fonte, R.; Porcelli, L.; et al. Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma. J. Exp. Clin. Cancer. Res. 2023, 42, 251.
134. Cordonnier, M.; Nardin, C.; Chanteloup, G.; et al. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients. J. Extracell. Vesicle. 2020, 9, 1710899.
135. Hur, J. Y.; Lee, K. Y. Characteristics and clinical application of extracellular vesicle-derived DNA. Cancers 2021, 13, 3827.
136. Waldenmaier, M.; Schulte, L.; Schönfelder, J.; et al. Comparative panel sequencing of DNA variants in cf-, ev- and tumorDNA for pancreatic ductal adenocarcinoma patients. Cancers 2022, 14, 1074.
137. Miceli, R. T.; Chen, T. Y.; Nose, Y.; et al. Extracellular vesicles, RNA sequencing, and bioinformatic analyses: challenges, solutions, and recommendations. J. Extracell. Vesicle. 2024, 13, e70005.
138. Li, M.; Yu, Y.; Liu, G.; et al. A promising frontier of circulating messenger RNA in liquid biopsy: from mechanisms to clinical applications. Int. J. Cancer. 2025, 157, 1519-37.
139. Bamodu, O. A.; Chung, C.; Pisanic, T. R. Harnessing liquid biopsies: exosomes and ctDNA as minimally invasive biomarkers for precision cancer medicine. J. Liquid. Biopsy. 2023, 2, 100126.
140. Sánchez-Herrero, E.; Serna-Blasco, R.; Robado De Lope, L.; González-Rumayor, V.; Romero, A.; Provencio, M. Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis. Front. Oncol. 2022, 12, 943253.
141. Tsering, T.; Nadeau, A.; Wu, T.; Dickinson, K.; Burnier, J. V. Extracellular vesicle-associated DNA: ten years since its discovery in human blood. Cell. Death. Dis. 2024, 15, 668.
142. Shen, Y.; Li, M.; Liao, L.; Gao, S.; Wang, Y. Plasma exosome-derived connexin43 as a promising biomarker for melanoma patients. BMC. Cancer. 2023, 23, 242.
143. Lim, S. Y.; Boyd, S. C.; Diefenbach, R. J.; Rizos, H. Circulating MicroRNAs: functional biomarkers for melanoma prognosis and treatment. Mol. Cancer. 2025, 24, 99.
144. De Martino, E.; Gandin, I.; Azzalini, E.; et al. A group of three miRNAs can act as candidate circulating biomarkers in liquid biopsies from melanoma patients. Front. Med. 2023, 10, 1180799.
145. Trilla-Fuertes, L.; Gámez-Pozo, A.; Laso-García, F.; et al. Protein content of extracellular vesicles from patients with advanced melanoma changes upon progression to anti-PD1 therapy. Sci. Rep. 2026, 16, 5891.
146. Bollard, S.; Howard, J.; Casalou, C.; et al. Proteomic and metabolomic profiles of plasma-derived Extracellular Vesicles differentiate melanoma patients from healthy controls. Transl. Oncol. 2024, 50, 102152.
147. Sirivolu, S.; Peng, C.; Neviani, P.; Xu, B. Y.; Berry, J. L.; Xu, L. Comparative single vesicle analysis of aqueous humor extracellular vesicles before and after radiation in uveal melanoma eyes. Int. J. Mol. Sci. 2024, 25, 6035.
148. Luz, Pessuti. C.; Fialho, Costa. D.; Ribeiro, K. S.; et al. Characterization of Extracellular vesicles isolated from different liquid biopsies of uveal melanoma patients. J. Circ. Biomark. 2022, 11, 36-47.
149. Beasley, A. B.; Chen, F. K.; Isaacs, T. W.; Gray, E. S. Future perspectives of uveal melanoma blood based biomarkers. Br. J. Cancer. 2022, 126, 1511-28.
150. Marsavela, G.; Mcevoy, A. C.; Pereira, M. R.; et al. Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. Br. J. Cancer. 2021, 126, 401-8.
151. De, Simoni. E.; Spagnolo, F.; Gandini, S.; et al. Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma. Cancer. Treat. Rev. 2024, 129, 102788.
152. Fathi, M.; Zarei, A.; Moghimi, A.; et al. Combined cancer immunotherapy based on targeting adenosine pathway and PD-1/PDL-1 axis. Expert. Opin. Ther. Targets. 2024, 28, 757-77.
153. Shan, Z.; Liu, F. Targeting ferroptosis, pyroptosis and necroptosis for cancer immunotherapy in melanoma: mechanistic insights and clinical perspectives. Front. Immunol. 2025, 16, 1629620.
154. Sato, Y. T.; Umezaki, K.; Sawada, S.; et al. Engineering hybrid exosomes by membrane fusion with liposomes. Sci. Rep. 2016, 6, 21933.
155. Lee, J.; Kim, J.; Na, K.; Ahn, H. GMP manufacturing of umbilical cord blood mesenchymal stem cell-released exosomes and verification of wound healing efficacy. Nanotheranostics 2025, 9, 95-109.
156. Yang, F.; Wang, M.; Guan, X. Exosomes and mimics as novel delivery platform for cancer therapy. Front. Pharmacol. 2022, 13, 1001417.
157. Thakur, A.; Sidu, R. K.; Zou, H.; Alam, M. K.; Yang, M.; Lee, Y. Inhibition of glioma cells’ proliferation by doxorubicin-loaded exosomes via microfluidics. Int. J. Nanomed. 2020, 15, 8331-43.
158. Zhao, Y.; Hang, R.; Li, H.; et al. Biomaterial surface-mediated macrophages exert immunomodulatory roles by exosomal CCL2-induced membrane integrin β1 trafficking in recipient cells. Adv. Sci. 2025, 12, 2409809.
159. Chen, J.; Zhang, G.; Wan, Y.; et al. Immune cell-derived exosomes as promising tools for cancer therapy. J. Controlled. Release. 2023, 364, 508-28.
160. Wang, W.; Jiang, Y.; Zhang, D.; et al. USP5 inhibition via bone marrow-targeted engineered exosomes for myeloproliferative neoplasms therapy. J. Nanobiotechnol. 2025, 23, 501.
161. Yin, Y.; Han, X.; Li, C.; et al. The status of industrialization and development of exosomes as a drug delivery system: a review. Front. Pharmacol. 2022, 13, 961127.
162. Nguyen, V. D.; Kim, H. Y.; Choi, Y. H.; Park, J.; Choi, E. Tumor-derived extracellular vesicles for the active targeting and effective treatment of colorectal tumors in vivo. Drug. Deliv. 2022, 29, 2621-31.
163. Zhan, Q.; Yi, K.; Qi, H.; et al. Engineering blood exosomes for tumor-targeting efficient gene/chemo combination therapy. Theranostics 2020, 10, 7889-905.
164. Jiang, L.; Gu, Y.; Du, Y.; Tang, X.; Wu, X.; Liu, J. Engineering exosomes endowed with targeted delivery of triptolide for malignant melanoma therapy. ACS. Appl. Mater. Interfaces. 2021, 13, 42411-28.
165. Liu, J.; Srivastava, S.; Li, T.; et al. On the feasibility of SERS-based monitoring of drug loading efficiency in exosomes for targeted delivery. Biosensors 2025, 15, 141.
166. Wu, J.; Jin, Z.; Fu, T.; et al. Extracellular vesicle-based drug delivery systems in cancer therapy. Int. J. Mol. Sci. 2025, 26, 4835.
167. Li, Z.; Ma, Y.; Ren, Y.; Lin, X.; Su, Z.; Zhang, S. Thermal-triggered loading and GSH-responsive releasing property of HBc particles for drug delivery. J. Controlled. Release. 2023, 362, 784-96.
168. Alvarez-erviti, L.; Seow, Y.; Yin, H.; Betts, C.; Lakhal, S.; Wood, M. J. A. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29, 341-5.
169. Wang, C.; Li, N.; Li, Y.; et al. Engineering a HEK-293T exosome-based delivery platform for efficient tumor-targeting chemotherapy/internal irradiation combination therapy. J. Nanobiotechnol. 2022, 20, 247.
170. Wu, K.; Chang, Y.; Chiang, R. Y.; Ding, D. CAP-LAMP2b-modified stem cells’ extracellular vesicles hybrid with CRISPR-Cas9 targeting ADAMTS4 to reverse IL-1β-induced aggrecan loss in chondrocytes. Int. J. Mol. Sci. 2025, 26, 9812.
171. Gu, Y.; Du, Y.; Jiang, L.; et al. αvβ3 integrin-specific exosomes engineered with cyclopeptide for targeted delivery of triptolide against malignant melanoma. J. Nanobiotechnol. 2022, 20, 384.
172. Kang, C.; Han, P.; Lee, J. S.; Lee, D.; Kim, D. Anchor, spacer, and ligand-modified engineered exosomes for trackable targeted therapy. Bioconjugate. Chem. 2020, 31, 2541-52.
173. Tian, Y.; Li, S.; Song, J.; et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014, 35, 2383-90.
174. Tian, J.; Han, Z.; Song, D.; et al. Engineered exosome for drug delivery: recent development and clinical applications. Int. J. Nanomed. 2023, 18, 7923-40.
175. Macdougall, L. J.; Wiley, K. L.; Kloxin, A. M.; Dove, A. P. Design of synthetic extracellular matrices for probing breast cancer cell growth using robust cyctocompatible nucleophilic thiol-yne addition chemistry. Biomaterials 2018, 178, 435-47.
176. Lim, G. T.; You, D. G.; Han, H. S.; et al. Bioorthogonally surface-edited extracellular vesicles based on metabolic glycoengineering for CD44-mediated targeting of inflammatory diseases. J. . Extracell. Vesicle. 2021, 10, e12077.
177. Aare, M.; Lazarte, J. M. S.; Muthu, M.; Rishi, A. K.; Singh, M. Genetically bio-engineered PD-L1 targeted exosomes for immunotherapy of resistant triple negative breast cancer. Drug. Deliv. Transl. Res. 2025, 16, 693-710.
178. Wang, J. S.; Yassin, S.; Lin, A. Y. Utilization of exosome-based therapies to augment anti-PD-1/PD-L1 therapies. J. Immunother. Cancer. 2025, 13, e010603.
179. Yin, Z.; Yu, M.; Ma, T.; et al. Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. J. Immunother. Cancer. 2021, 9, e001698.
180. Salunkhe, S.; Dheeraj; Basak, M.; Chitkara, D.; Mittal, A. Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: strategies and significance. J. Controlled. Release. 2020, 326, 599-614.
181. Bolaños, K.; León, D.; Jara-Guajardo, P.; et al. In vivo targeted delivery of extracellular vesicle-gold nanorod hybrids to metastatic melanoma lung tumors. Int. J. Nanomed. 2025, 20, 6983-98.
182. Chen, H.; Jiang, Y.; Li, X. Adriamycin-loaded exosome with anti-CD20 aptamers selectively suppresses human CD20+ melanoma stem cells. Skin. Res. Technol. 2022, 29, e13259.
183. Li, L.; He, D.; Guo, Q.; et al. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer. J. Nanobiotechnol. 2022, 20, 50.
184. Xie, Q.; Gao, Y.; Chen, W.; et al. Membrane fusogenic liposomes facilitate the production of immunostimulatory extracellular vesicles for enhanced cancer therapy. J. Mater. Chem. B. 2025, 13, 7490-501.
185. Lee, Y.; Huang, C. Engineered perfluorochemical cancer-derived exosomes loaded with indocyanine green and camptothecin provide targeted photochemotherapy for effective cancer treatment. Int. J. Nanomed. 2025, 20, 327-42.
186. Ho, M. Y.; Liu, S.; Xing, B. Bacteria extracellular vesicle as nanopharmaceuticals for versatile biomedical potential. Nano. Converg. 2024, 11, 28.
187. Gao, Y.; Liu, J.; Wu, M.; et al. Photosensitive hybrid γδ-T exosomes for targeted cancer photoimmunotherapy. ACS. Nano. 2025, 19, 4251-68.
188. Zhang, M.; Hu, S.; Liu, L.; et al. Engineered exosomes from different sources for cancer-targeted therapy. Sig. Transduct. Target. Ther. 2023, 8, 124.
189. Hazekawa, M.; Nishinakagawa, T.; Hosokawa, M.; Ishibashi, D. Development of an organ-directed exosome-based siRNA-carrier derived from autologous serum for lung metastases and testing in the B16/BL6 spontaneous lung metastasis model. Pharmaceutics 2022, 14, 815.
190. Santos, N. L.; Bustos, S. O.; Reis, P. P.; Chammas, R.; Andrade, L. N. S. Extracellular vesicle-packaged miR-195-5p sensitizes melanoma to targeted therapy with kinase inhibitors. Cells 2023, 12, 1317.
191. Park, J. H.; Lee, S.; Jeon, H.; et al. A novel convex acoustic lens-attached ultrasound drug delivery system and its testing in a murine melanoma subcutaneous model. Int. J. Pharm. 2023, 642, 123118.
192. Duan, M.; Chen, B.; Yi, X.; et al. Doxorubicin delivery by pYEEIE peptide-functionalized rhodiola rosea-derived exosome-like nanovesicles for targeted melanoma therapy. Front. Pharmacol. 2025, 16, 1619998.
193. Lee, J. H.; Song, J.; Kim, I. G.; et al. Exosome-mediated delivery of transforming growth factor-β receptor 1 kinase inhibitors and toll-like receptor 7/8 agonists for combination therapy of tumors. Acta. Biomater. 2022, 141, 354-63.
194. Huang, C.; Zhou, Y.; Feng, X.; Wang, J.; Li, Y.; Yao, X. Delivery of engineered primary tumor-derived exosomes effectively suppressed the colorectal cancer chemoresistance and liver metastasis. ACS. Nano. 2023, 17, 10313-26.
195. Ehexige, E.; Bao, M.; Bazarjav, P.; et al. Silencing of STAT3 via peptidomimetic LNP-mediated systemic delivery of RNAi downregulates PD-L1 and inhibits melanoma growth. Biomolecules 2020, 10, 285.
196. Faruqu, F. N.; Wang, J. T.; Xu, L.; et al. Membrane radiolabelling of exosomes for comparative biodistribution analysis in immunocompetent and immunodeficient mice - a novel and universal approach. Theranostics 2019, 9, 1666-82.
197. Villa, A.; Crescenti, D.; De, Mitri. Z.; et al. Preclinical pharmacology of patient-derived extracellular vesicles for the intraoperative imaging of tumors. Theranostics 2024, 14, 6301-18.
198. Sadeghi, S.; Tehrani, F. R.; Tahmasebi, S.; Shafiee, A.; Hashemi, S. M. Exosome engineering in cell therapy and drug delivery. Inflammopharmacology 2023, 31, 145-69.
199. Antimisiaris, S. G.; Mourtas, S.; Marazioti, A. Exosomes and exosome-inspired vesicles for targeted drug delivery. Pharmaceutics 2018, 10, 218.
200. Kostyusheva, A.; Romano, E.; Yan, N.; Lopus, M.; Zamyatnin, A. A.; Parodi, A. Breaking barriers in targeted therapy: advancing exosome Isolation, Engineering, and imaging. Adv. Drug. Delivery. Rev. 2025, 218, 115522.
201. Zhao, S.; Di, Y.; Fan, H.; et al. Targeted delivery of extracellular vesicles: the mechanisms, techniques and therapeutic applications. Mol. Biomed. 2024, 5, 60.
202. Hu, M.; Han, Y.; Zhang, X.; et al. Extracellular vesicles for targeted drug delivery: advances in surface modification strategies and therapeutic applications. J. Transl. Med. 2025, 23, 1028.
203. Leary, N.; Walser, S.; He, Y.; et al. Melanoma-derived extracellular vesicles mediate lymphatic remodelling and impair tumour immunity in draining lymph nodes. J. Extracell. Vesicle. 2022, 11, e12197.
204. Zhang, W.; Zhong, W.; Wang, B.; et al. ICAM-1-mediated adhesion is a prerequisite for exosome-induced T cell suppression. Dev. Cell. 2022, 57, 329-43.e7.
205. Jackson Cullison, S. R.; Flemming, J. P.; Karagoz, K.; Wermuth, P. J.; Mahoney, M. G. Mechanisms of extracellular vesicle uptake and implications for the design of cancer therapeutics. J. Extracell. Bio. 2024, 3, e70017.
206. Song, H.; Chen, X.; Hao, Y.; Wang, J.; Xie, Q.; Wang, X. Nanoengineering facilitating the target mission: targeted extracellular vesicles delivery systems design. J. Nanobiotechnol. 2022, 20, 431.
207. Bader, J.; Brigger, F.; Leroux, J. Extracellular vesicles versus lipid nanoparticles for the delivery of nucleic acids. Adv. Drug. Delivery. Rev. 2024, 215, 115461.
208. Gandek, T. B.; Van Der Koog, L.; Nagelkerke, A. A comparison of cellular uptake mechanisms, delivery efficacy, and intracellular fate between liposomes and extracellular vesicles. Adv. Healthc. Mater. 2023, 12, 2300319.
209. Nieuwland, R.; Siljander, P. R. M. A beginner's guide to study extracellular vesicles in human blood plasma and serum. J. Extracell. Vesicle. 2024, 13, e12400.
210. György, B.; Pálóczi, K.; Balbisi, M.; et al. Effect of the 35 nm and 70 nm size exclusion chromatography (SEC) column and plasma storage time on separated extracellular vesicles. Curr. Issues. Mol. Biol. 2024, 46, 4337-57.
211. Alter, C. L.; Lotter, C.; Puligilla, R. D.; et al. Nano plasma membrane vesicle-lipid nanoparticle hybrids for enhanced gene delivery and expression. Adv. Healthc. Mater. 2024, 14, 2401888.
212. Li, Q.; Li, Y.; Shao, J.; et al. Exploring regulatory frameworks for exosome therapy: insights and perspectives. Health. Care. Sci. 2025, 4, 299-309.
213. Mizenko, R. R.; Feaver, M.; Bozkurt, B. T.; et al. A critical systematic review of extracellular vesicle clinical trials. J. Extracell. Vesicle. 2024, 13, e12510.
214. Sun, D.; Zhuang, X.; Xiang, X.; et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther. 2010, 18, 1606-14.
215. Wahlgren, J.; Karlson, T. D. L.; Brisslert, M.; et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic. Acids. Res. 2012, 40, e130.
216. Kim, M. S.; Haney, M. J.; Zhao, Y.; et al. Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomed. Nanotechnol. Biol. Med. 2016, 12, 655-64.
217. Guo, P.; Busatto, S.; Huang, J.; Morad, G.; Moses, M. A. A facile magnetic extrusion method for preparing endosome-derived vesicles for cancer drug delivery. Adv. Funct. Mater. 2021, 31, 2008326.
218. Ohno, S.; Takanashi, M.; Sudo, K.; et al. Systemically injected exosomes targeted to EGFR deliver antitumor MicroRNA to breast cancer cells. Mol. Ther. 2013, 21, 185-91.
219. Pham, T. C.; Jayasinghe, M. K.; Pham, T. T.; et al. Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery. J. Extracell. Vesicle. 2021, 10, e12057.
220. Smyth, T.; Petrova, K.; Payton, N. M.; et al. Surface functionalization of exosomes using click chemistry. Bioconjugate. Chem. 2014, 25, 1777-84.
221. Ferraz, L. S.; Souza, A. S. O.; Rodrigues, T.; Cabral-Castro, M. J. Liquid biopsy as a potential tool for diagnosis and clinical monitoring of cutaneous and uveal melanoma. J. Liquid. Biopsy. 2025, 9, 100306.
222. Uman, S.; Worthington, K.; Dominic, J.; Atluri, P.; Burdick, J. A. Comparison of technologies for manufacturing extracellular vesicles for therapeutic applications. Trends. Biotechnol. 2026, 44, 1079-99.
